Zacks Investment Research on MSN18h
APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority TagApellis Pharmaceuticals APLS announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback